Posted by Michael Wonder on 01 Aug 2023
FDA grants QIDP designation for Kinnear's CSA-131 drug for life-threatening Pseudomonas bacterial infections in CF
31 July 2023 - Kinnear Pharmaceuticals today announced the US FDA has granted qualified infectious disease product designation for CSA-131 for the prevention and treatment of life threatening Pseudomonas infections in patients with cystic fibrosis.
CSA-131 is a synthetic non-peptide mimic of the endogenous antimicrobial peptide LL-37 which forms a key component of the body’s innate immune system which is essential to preventing and treating lung infections.
